Expert debate: should anti-CD20 therapy continue indefinitely in patients with multiple sclerosis?

Experts at ECTRIMS 2021 debated whether anti-CD20 therapy should continue indefinitely on a fixed schedule in patients with multiple sclerosis (MS).

Based on safety and efficacy data from clinical trials, anti-CD20 monoclonal antibody therapy is rapidly becoming one of the preferred modes of treatment for MS, according to Professor Jiwon Oh of the University of Toronto in Toronto, Canada, who chaired the debate. However, MS is a chronic, lifelong condition, and extended dosing intervals could potentially improve clinical outcomes.